MS and Demyelinating Disorders

The assistant professor at Hunter College talked about the importance of prioritizing accurate localization, appropriate diagnostic tests, and patient communication for effective neurological diagnosis, prognosis, and treatment. [WATCH TIME: 3 minutes]

Among a cohort of more than 70 individuals with MS, only 1 relapse occurred while on eculizumab, with significant reductions in immunosuppressive use observed.

The director of the Buffalo Neuroimaging Analysis Center talked about a study that explored cognitive decline in patients with early multiple sclerosis, underlining the significance of addressing cognitive impairment in the early stages of the disease. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

IMU-838, or vidofludimus calcium, has shown promising results in studies of patients with relapsing-remitting multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 18, 2023.

The executive vice president of the National MS Society discussed the challenges with treating progressive forms of MS, and the accumulating neurodegeneration seen over time. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is general neurology.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 11, 2023.

Catch up on any of the neurology news headlines you may have missed over the course of July 2023, compiled all into one place by the NeurologyLive® team.

Results showed that 67% of treated patients in Stage A demonstrated evidence of clinical improvement, indicating that IgG autoantibodies play a significant role in the underlying biology of CIDP.

The executive vice president of the National MS Society provided insight on the Pathways to Cures roadmap, a global initiative to stop multiple sclerosis, restore function, and end MS.

Bruce Cree, MD, PhD, MAS, presents his final thoughts for clinicians on the safety, efficacy, and tolerability of sphinogine-1-phospate (S1P) receptor modulators in the treatment of multiple sclerosis (MS).

Bruce Cree, MD, PhD, MAS, discusses new data presented at the 2023 European Academy of Neurology (EAN) congress on BTK inhibitors, such as Tolebrutinib, evobrutinib, renibrutinib, and fenibrutinib. Dr Cree also highlights important safety information and adverse events identified in these studies.

Bruce Cree, MD, PhD, MAS, provides his clinical advice on managing treatment cessation of sphinogine-1-phospate (S1P) receptor modulators while preventing multiple sclerosis (MS) disease rebound.

Bruce Cree, MD, PhD, MAS, discusses how sphinogine-1-phospate (S1P) receptor modulators may suppress a patients immune system and key considerations clinicians should make in light of this.

Bruce Cree, MD, PhD, MAS, reviews the results of the long-term efficacy and safety study of ozanimod, DAYBREAK, in relapsing-remitting multiple sclerosis (RRMS) published last year. Dr Cree also discusses two other safety studies presented at the 2023 European Academy of Neurology (EAN) congress.

In the supporting phase 3 study, treatment with GA Depot resulted in statistically significant reductions in annualized relapse rate, the primary end point, and other secondary outcomes of T1 and T2 hyperintense lesions.

Bruce Cree, MD, PhD, MAS, discusses key considerations when selecting one of the four FDA approved sphinogine-1-phospate (S1P) receptor modulators for multiple sclerosis (MS). Dr Cree also highlights a particular adverse event observed in the extension studies of these four S1P receptor modulators.

Bruce Cree, MD, PhD, MAS, discusses the pathophysiology of multiple sclerosis (MS) and how sphinogine-1-phospate (S1P) receptor modulators address the underlying causes. Dr Cree also discusses the differences between the four FDA approved drugs for MS: fingolimod, siponimod, ozanimod, and ponesimod.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Neurology News Network for the week ending August 5, 2023. [WATCH TIME: 4 minutes]